<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04563260</url>
  </required_header>
  <id_info>
    <org_study_id>AJIRB-MED-THE-20-174</org_study_id>
    <nct_id>NCT04563260</nct_id>
  </id_info>
  <brief_title>Effect of Palonosetron on Remifentanil for Preventing Emergence Cough in Female</brief_title>
  <official_title>Effect of Palonosetron on Effect-site Concentration of Remifentanil for Preventing Emergence Cough During General Anesthesia in Female Patients Undergoing Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ajou University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate the optimal Ce of remifentanil for&#xD;
      preventing emergence cough following extubation during general anesthesia in female patients&#xD;
      who receive the palonosetron or not.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug&#xD;
      effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases&#xD;
      the at-risk time during extubation. In addition, cough suppression of remifentanil enables&#xD;
      smooth extubation with reduced complications. However, the infusion of remifentanil&#xD;
      suppresses the emergence cough effectively in clinical practice, whereas it still delays the&#xD;
      awakening from anesthesia, resulting in prolonged emergence time. Reduced Ce of remifentanil&#xD;
      during emergence would decrease the adverse events that are associated with remifentanil&#xD;
      infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Actual">March 19, 2021</completion_date>
  <primary_completion_date type="Actual">March 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>optimal Ce of remifentanil</measure>
    <time_frame>From the end of surgery until the time of endotracheal extubation, about 20 minutes</time_frame>
    <description>Using Dixon methods, evaluating of optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Gallbladder Diseases</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group receives the intravenous normal saline 2 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palonosetron group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palonosetron group receives the intravenous palonosetron 1.5 mL (0.075 mg) + normal saline 0.5 mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline injection</intervention_name>
    <description>Normal saline 2 mL, intravenous injection</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron Injection [Aloxi]</intervention_name>
    <description>Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection</description>
    <arm_group_label>Palonosetron group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Laparoscopic cholecystectomy under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2, respiratory infection, uncontrolled hypertension&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ajou University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ji Eun Kim</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallbladder Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

